Indeed, as described above, there is ample evidence that metformin administration can ameliorate skeletal muscle loss and function due to glutaredoxin-1 deficiency, obesity, or sarcopenia. Here, GLRX is linked to obesity due to melanocortin 4 receptor deficiency.